MX2023012032A - Composiciones y métodos para tratar la miastenia gravis pediátrica. - Google Patents
Composiciones y métodos para tratar la miastenia gravis pediátrica.Info
- Publication number
- MX2023012032A MX2023012032A MX2023012032A MX2023012032A MX2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- myasthenia gravis
- treating pediatric
- pediatric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US202263266880P | 2022-01-18 | 2022-01-18 | |
| PCT/US2022/024354 WO2022221239A1 (en) | 2021-04-12 | 2022-04-12 | Compositions and methods for treating pediatric myasthenia gravis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012032A true MX2023012032A (es) | 2023-12-08 |
Family
ID=83640966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012032A MX2023012032A (es) | 2021-04-12 | 2022-04-12 | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240182598A1 (https=) |
| EP (1) | EP4323002A4 (https=) |
| JP (1) | JP2024517087A (https=) |
| KR (1) | KR20230169207A (https=) |
| AU (1) | AU2022256389A1 (https=) |
| BR (1) | BR112023021046A2 (https=) |
| CA (1) | CA3216642A1 (https=) |
| CL (1) | CL2023003033A1 (https=) |
| IL (1) | IL307445A (https=) |
| JO (1) | JOP20230247A1 (https=) |
| MX (1) | MX2023012032A (https=) |
| PH (1) | PH12023552841A1 (https=) |
| WO (1) | WO2022221239A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| WO2019160979A1 (en) * | 2018-02-13 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| WO2020023310A1 (en) * | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
-
2022
- 2022-04-12 US US18/286,455 patent/US20240182598A1/en active Pending
- 2022-04-12 BR BR112023021046A patent/BR112023021046A2/pt unknown
- 2022-04-12 JP JP2023562610A patent/JP2024517087A/ja active Pending
- 2022-04-12 AU AU2022256389A patent/AU2022256389A1/en active Pending
- 2022-04-12 IL IL307445A patent/IL307445A/en unknown
- 2022-04-12 WO PCT/US2022/024354 patent/WO2022221239A1/en not_active Ceased
- 2022-04-12 CA CA3216642A patent/CA3216642A1/en active Pending
- 2022-04-12 MX MX2023012032A patent/MX2023012032A/es unknown
- 2022-04-12 PH PH1/2023/552841A patent/PH12023552841A1/en unknown
- 2022-04-12 EP EP22788750.2A patent/EP4323002A4/en active Pending
- 2022-04-12 KR KR1020237038171A patent/KR20230169207A/ko active Pending
-
2023
- 2023-10-11 CL CL2023003033A patent/CL2023003033A1/es unknown
- 2023-10-12 JO JOJO/P/2023/0247A patent/JOP20230247A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20230247A1 (ar) | 2023-10-12 |
| EP4323002A4 (en) | 2025-04-16 |
| WO2022221239A1 (en) | 2022-10-20 |
| KR20230169207A (ko) | 2023-12-15 |
| JP2024517087A (ja) | 2024-04-19 |
| BR112023021046A2 (pt) | 2023-12-19 |
| AU2022256389A1 (en) | 2023-11-30 |
| IL307445A (en) | 2023-12-01 |
| CL2023003033A1 (es) | 2024-03-08 |
| PH12023552841A1 (en) | 2024-05-20 |
| AU2022256389A9 (en) | 2023-12-07 |
| CA3216642A1 (en) | 2022-10-20 |
| EP4323002A1 (en) | 2024-02-21 |
| US20240182598A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000220A (es) | Anticuerpos il-11 | |
| CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
| CO2019013010A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| BR112019012342A2 (pt) | anticorpos il-11 | |
| CY1121197T1 (el) | Il2rbhta/koinhς γαμμα αλυσου αντισωματα | |
| CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
| DOP2020000236A (es) | Anticuerpos il-1 1ra | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| MX393066B (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
| IL285923A (en) | Compositions, methods, and kits for delivery of polyribonucleotides | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| MX2020010946A (es) | Anticuerpos multiespecificos y usos del mismo. | |
| CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
| PE20201464A1 (es) | Conjugados anticuerpo anti-cd40-farmaco | |
| UY36889A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
| CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| CR20180031A (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso | |
| AR061246A1 (es) | Anticuerpos anti- dill4 y metodos que los usan | |
| IL281504A (en) | Methods and kits for preparing pathogen-inactivated whole blood | |
| CL2023001052A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| IL304403A (en) | Multispecific antibodies having specificity for ror1 and cd3 | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| UY39324A (es) | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. |